VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 2, 2005--Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) today announced that it has started dosing subjects in a US Phase II trial for its cholesterol-lowering drug, FM-VP4. The primary efficacy objective of this trial is to determine the effect of two doses of FM-VP4, 450mg and 900mg, given for 12 weeks, compared to placebo, on low density lipoprotein-cholesterol (LDL-C). The goal of this trial is to demonstrate a minimum of 15% reduction from baseline in LDL-C at Week 12. The trial is expected to be completed in the third quarter of 2006.
